- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
ImmuCell Corporation(ICCC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ICCC
11/13/2026: ICCC (2-star) is currently NOT-A-BUY. Pass it for now.
ImmuCell Corporation is a specialized animal health biotechnology company that develops natural passive immunity and diagnostic products to enhance livestock productivity. Its primary operational strength stems from the established First Defense product line, which drives steady baseline revenues in neonatal calf care. The key investment growth story centers on expanding market penetration and advancing late-stage pipeline treatments like Re-Tain. However, the company faces notable risks, including high product concentration, intense competition from major pharmaceutical conglomerates, and regulatory execution uncertainties. The stock suits growth-oriented or speculative investors willing to navigate micro-cap volatility while monitoring clinical and commercial milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers niche biotechnology growth potential tied to new product adoption, though overall revenue scale remains relatively small. |
| Momentum investor | Strong fit while signal remains positive | Momentum participants may target the stock during periods of favorable earnings reports or regulatory catalysts. |
| Value investor | Mixed fit | Valuation multiples can appear elevated relative to current earnings due to heavy reinvestment in pipeline drug development. |
| Dividend investor | Weak fit | ImmuCell does not pay a dividend, prioritizing internal reinvestment over cash distributions. |
| Low-risk investor | Weak fit | Micro-cap biotechnology exposure introduces considerable stock price volatility and operational execution risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Micro-cap stock liquidity can lead to sharp share price fluctuations on modest trading volume. |
| Valuation risk | Medium / high | The stock's valuation is sensitive to shifts in profitability and clinical pipeline expectations. |
| Competition risk (animal health giants) | High | Well-capitalized competitors possess greater resources to market alternative veterinary products. |
| Business quality | Medium | ImmuCell maintains proprietary technology and loyal customer niches, but operates with limited financial scale. |
| Dividend income | Low / none | No dividend is distributed to shareholders. |
| Execution risk | High | Success depends heavily on regulatory approvals and commercial scaling of new product candidates like Re-Tain. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 97.73M USD | Price to earnings Ratio 56.58 | 1Y Target Price 14 |
Price to earnings Ratio 56.58 | 1Y Target Price 14 | ||
Volume (30-day avg) 8.9K shares | Beta 0.62 | 52 Weeks Range 4.52 - 12.10 | Updated Date 11/15/2026 |
52 Weeks Range 4.52 - 12.10 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.19 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 5.53% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Scours Segment (First Defense) | Sales of orally delivered passive antibody products designed to prevent scours in newborn dairy and beef calves. | This is the primary engine generating the majority of the company's current revenues. |
| Mastitis Segment (CMT & Diagnostics) | Sales of the California Mastitis Test reagents and equipment for on-farm milk quality testing. | Provides a steady complementary revenue stream while newer treatments are developed. |
| Geographic Markets | Distribution across the United States and international dairy markets primarily via veterinary and agricultural distributors. | Exposes the business primarily to domestic dairy and beef farm economic conditions. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-12 | When After Market | Estimate - | Actual 0.1 |
Profitability
Profit Margin 2.57% | Operating Margin (TTM) 15.21% |
Management Effectiveness
Return on Assets (TTM) 6.25% | Return on Equity (TTM) 2.57% |
Valuation
Trailing PE 56.58 | Forward PE - | Enterprise Value 101.83M | Price to Sales(TTM) 3.19 |
Enterprise Value 101.83M | Price to Sales(TTM) 3.19 | ||
Enterprise Value to Revenue 3.07 | Enterprise Value to EBITDA 22.78 | Shares Outstanding 9.09M | Shares Floating 6.03M |
Shares Outstanding 9.09M | Shares Floating 6.03M | ||
Percent Insiders 32.09 | Percent Institutions 20.39 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

